Black Titan (NASDAQ:BTTC – Get Free Report) issued its earnings results on Friday. The company reported ($0.10) EPS for the quarter, FiscalAI reports.
Black Titan Price Performance
NASDAQ BTTC opened at $0.28 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.62 and a current ratio of 4.62. The company has a fifty day moving average of $0.43 and a 200 day moving average of $0.97. Black Titan has a 1 year low of $0.28 and a 1 year high of $10.05.
Black Titan Company Profile
Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
Further Reading
- Five stocks we like better than Black Titan
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
- Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?
- MarketBeat Week in Review – 11/2 – 11/6
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
Receive News & Ratings for Black Titan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Titan and related companies with MarketBeat.com's FREE daily email newsletter.
